drugset / Trial / NCT04449250

Fed-Fast Crossover Study to Assess the Effect of Food With CTx-1301 in Healthy Subjects

NCT04449250

Phase 1 Completed 27 enrolled Cingulate Therapeutics
RandomizedCrossoverOpen-labelOther

Summary

The primary purpose of this study is to assess the effect of food on the rate and extent of absorption and the overall bioavailability of a single dose of CTx-1301 25 mg trimodal tablets in healthy adult volunteers.

Timeline

Start
2022-09-14
Primary completion
2022-10-14
Completion
2022-10-14

Drugs

EvaluationDrugModalityDoseRoute
Comparator dexmethylphenidate Unknown 25 mg

Indications

No indication recorded.